GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.98 (+1.00%)

Growth Price

Fairly valued

Stability Price

Overvalued by 61.20%

Company Metrics

  • P/E 10.47
  • P/S 4.94
  • P/B 8.88
  • EPS 9.48
  • Cash ROIC 43.15%
  • Cash Ratio 1.76
  • Dividend 1.72 / 1.75%
  • Avg. Vol. 11.52M
  • Shares 1.65B
  • Market Cap. 145.67B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Gilead Sciences, Inc. (GILD) Letairis Wins FDA Nod For PAH: Stock To Recover Soon
Bidness ETC - 20 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD), the undisputed leader in the hepatitis C drugs market, has another victory to add to its long-established success story.
Healthcare Movers to Observe: Gilead Sciences, Inc. (NASDAQ:GILD), Eli Lilly ... - Wsnews4investors
Gilead Sciences Inc. (NASDAQ:GILD) Successfully Attains Authorization of Use ... - StreetWise Report (press release)
Gilead Sciences, Inc. (GILD): Here's why Morgan Stanley Downgraded The Stock
Bidness ETC - 21 hours ago
Mr. Harrison downgraded Gilead Sciences, Inc. (NASDAQ:GILD) from Overweight to Equal Weight, but maintained a price target of $127 on the stock.
Why John Martin Sold 150000 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)? -
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Sees Large Outflow of Money - News Watch International
Clovis Oncology Now Too Good To Ignore Gilead Sciences, Roche Take Note
Bidness ETC - 20 hours ago
Clovis Oncology Inc. (NASDAQ:CLVS) is a small, $3.40 billion company focused on anti-cancer treatments - a lucrative area of medicine, expected to reach $147 billion in global spending by 2018.
New Stock downgrades: Gilead Sciences Inc (GILD), Regeneron Pharmaceuticals ...
Wall Street Point - 23 hours ago
Analyst recommendations are like dairy products in that it is best to use them quickly or not at all. Shares tend to drift in the direction of recommendation changes, but for weeks or months, not years.
Short-Term Hep C Sluggishness No Big Problem for Gilead Sciences, Inc.
Motley Fool - Sep 24, 2015
Hepatitis C drugs Sovaldi and Harvoni have become two of the biggest blockbusters on the market. In the process, they helped drive shares of biotech Gilead Sciences (NASDAQ:GILD) up by almost 200% since the beginning of 2013. Now, though, some ...
Biotech Stocks (IBB) Crash; Gilead Sciences, Inc. (GILD) And Amgen Inc (AMGN ... - Bidness ETC
Gilead Sciences (GILD) Stock Climbs on Strong Prescription Numbers -
5 Reasons I'm Buying More Gilead Sciences Inc.
Motley Fool - Sep 16, 2015
A few months ago, I finally decided to purchase shares in Gilead Sciences (NASDAQ: GILD), which was a stock I'd had on my radar for a long time, but I had just never been smart enough to add it to my personal portfolio.
Gilead Sciences Inc. (GILD) Stock Update - Plans To Boost Growth Rates - Bidness ETC
My Thoughts On Gilead Sciences' Capital Raise - Seeking Alpha
Needham's Q4 Insights: Gilead Sciences, Inc. (GILD), Intercept Pharmaceuticals ...
Smarter Analyst - Sep 30, 2015
In light of upcoming events in the biotechnology sector slated for the fourth quarter of this year, Needham analyst Alan Carr weighed in on a handful of biotech stocks including Gilead Sciences, Inc. (NASDAQ:GILD), Intercept Pharmaceuticals Inc ...
Time To Buy Gilead Sciences, Inc. (GILD) Stock
Bidness ETC - Sep 30, 2015
The current weak position of Gilead Sciences Inc. (NASDAQ:GILD) has created a golden opportunity for investors to buy its stock that has been tumbling for the past six trading sessions.
Gilead Sciences, Inc. (NASDAQ:GILD) Analyst Rating Update - Money Flow Index
Buy Gilead Sciences At An Attractive Price - Seeking Alpha
Morgan Stanley On Big Biotech: Upgrades, Pfizer, Vertex, Alexion, Cuts Gilead ...
Benzinga - Oct 2, 2015
Analyst Matthew Harrison downgraded the rating on Gilead Sciences, Inc. (NASDAQ: GILD) from Overweight to Equal-weight, while maintaining a price target of $127.
Why Morgan Stanley Downgraded Gilead, Valeant & Regeneron - Barron's (blog)
Is Gilead Sciences Worth $98?
Seeking Alpha - Oct 1, 2015
And due to requests from my previous article on my case for Apple (NASDAQ:AAPL) based on the numbers, I'll take a similar approach with Gilead Sciences. When I look at a company, I prefer not to use a cookie-cutter method. With Apple, I focused on FCF ...
Analyst Downgrades: Dunkin Brands Group Inc, Gilead Sciences, Inc., and ... - Schaeffers Research (blog)
Morgan Stanley Downgrades Gilead Sciences (GILD) to Equal-weight with Price ... - News Watch International